Global Leading Market Research Publisher QYResearch announces the release of its latest report “Chronic Disease Dietary Management Plan - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Chronic Disease Dietary Management Plan market, including market size, share, demand, industry development status, and forecasts for the next few years. For patients with chronic diseases (diabetes, hypertension, fatty liver, cardiovascular disease, obesity), medication alone is often insufficient to control metabolic indicators. Dietary mismanagement—excess sugar, sodium, saturated fat—leads to poor glycemic control (HbA1c >7%), elevated blood pressure (>130/80 mmHg), and disease progression. Chronic disease dietary management plans address this by providing integrated comprehensive management services that develop scientific, personalized dietary nutrition intervention strategies based on individual disease types and physical conditions. These services combine food selection, nutritional matching, dietary behavior guidance, and long-term health monitoring to help patients improve metabolic indicators, delay disease progression, and enhance quality of life. The global market was valued at US1,690millionin2025andisprojectedtoreachUS 3,719 million by 2032, growing at a CAGR of 12.1%. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/reports/6094551/chronic-disease-dietary-management-plan 1. Market Size & Share Outlook: Digital Health and Personalized Nutrition Drive Growth The chronic disease dietary management market is experiencing rapid growth (12.1% CAGR), driven by rising chronic disease prevalence (diabetes, hypertension, obesity), digital health adoption (mobile apps, CGM), and employer wellness programs. The market is moderately fragmented, with leading players—Noom, Livongo (Teladoc), Hinge Health, Dexcom, Amwell, Nutrino, Zoe, Lumen, DayTwo, Nutritics, Bitesnap, Nutrix, Spoon Guru, Abbott, Gushengtang Holdings, Dong-E-E-Jiao, Miaoyijia, Ping An Healthcare, WeDoctor, Shanzhen—holding 30-35% of global market share. North America is the largest market (45-50% share), followed by Europe (25-30%) and Asia-Pacific (15-20%, fastest-growing). Recent market intelligence (Q1 2026): Preliminary supply-side data indicates market share growth for multi-disease comprehensive plans (60-65% of market), which address multiple conditions (e.g., diabetes + hypertension + obesity). Single disease management plans (35-40%) focus on one condition. Segment by application: Healthcare industry (hospitals, clinics, telehealth) accounts for 50-55% of demand. Elderly care industry (nursing homes, assisted living) accounts for 20-25%. Health science industry (wellness centers, corporate wellness) accounts for 15-20%. Others (home health, insurance) account for 5-10%. 2. Technology Deep Dive: Single vs. Multi-Disease Management Plans Chronic disease dietary management integrates clinical guidelines (ADA for diabetes, ACC/AHA for hypertension, AASLD for fatty liver), personal data (CGM glucose, blood pressure, weight, food logs), and behavioral science (habit formation, coaching). Multi-Disease Comprehensive Plan (60-65% market share) – Addresses multiple chronic conditions simultaneously (e.g., diabetes + hypertension + dyslipidemia + obesity). Nutritional recommendations integrate conflicting needs: sodium reduction (hypertension) + carbohydrate control (diabetes) + saturated fat reduction (dyslipidemia) + calorie deficit (obesity). Examples: Noom (weight loss + prediabetes), Livongo (diabetes + hypertension), Zoe (metabolic health + gut microbiome). Price: US$ 50-150/month. Single Disease Management Plan (35-40% market share) – Focuses on one condition: diabetes (carbohydrate counting, glycemic index, CGM integration), hypertension (DASH diet, sodium reduction), fatty liver (low-sugar, low-saturated fat), CKD (protein restriction, potassium/phosphate control). Examples: DayTwo (diabetes, microbiome-based), Lumen (metabolic flexibility), Nutrino (diabetes, pregnancy). Price: US$ 30-80/month. Industry insight (digital health integration): Continuous glucose monitors (CGM, Dexcom G7, Abbott Freestyle Libre 3) provide real-time glucose data (288 readings/day). Dietary management apps integrate CGM data to provide meal feedback (postprandial glucose spikes). CGM + dietary management reduces HbA1c by 1-2% (vs. 0.5-1% for dietary alone). Reimbursement: US Medicare covers CGM for insulin-dependent diabetes; employer wellness programs cover dietary management (US$ 500-1,500/year per employee). 3. Market Drivers: Chronic Disease Epidemic, Digital Health, and Employer Wellness First, chronic disease prevalence. Global diabetes: 540 million adults (IDF 2025), projected 643 million by 2030. Hypertension: 1.3 billion adults (WHO). Obesity: 650 million adults (WHO). Fatty liver disease (NAFLD): 25-30% of adults (1.5-2 billion). Dietary management is first-line therapy for all these conditions (ADA, ACC/AHA, AASLD guidelines). Only 10-20% of patients receive structured dietary management (gap = 80-90% addressable market). Second, digital health and CGM adoption. CGM users: 5-10 million globally (2025), growing 15-20% annually. Medicare covers CGM for type 1 and insulin-dependent type 2 diabetes (7-8 million US beneficiaries). Dietary management apps integrate with CGM (Dexcom API, LibreView, Abbott). Personalized nutrition based on real-time glucose data (individualized carbohydrate tolerance) improves outcomes. Third, employer wellness programs and value-based care. US employers spend US500−1,000billionannuallyonhealthcare.Diabetes(US 10,000-15,000/year per employee) and hypertension (US5,000−8,000)drivecosts.Dietarymanagementprogramsreducemedicalclaimsby10−30 2,000-3,000 per participant. Employers (self-insured) cover dietary management as preventive benefit (US$ 500-1,500/year). Typical user case (Q4 2025): A 55-year-old male with type 2 diabetes (HbA1c 8.2%), hypertension (150/90 mmHg), and obesity (BMI 32) joined a multi-disease dietary management program (Noom, 6 months). Program components: personalized calorie budget (1,800 kcal/day), macronutrient targets (carbs 45%, protein 25%, fat 30%), sodium limit (2,300 mg/day), CGM integration (Dexcom G7), weekly coaching (10-15 minute calls), behavioral psychology (cognitive behavioral therapy, habit formation). Results: HbA1c reduced from 8.2% to 7.1% (1.1% reduction). Blood pressure reduced from 150/90 to 135/85 mmHg. Weight loss: 12 kg (BMI 32 to 28). Program cost: US60/month×6months=US 360. Estimated healthcare savings: US3,000−5,000annually(reducedmedications,fewercomplications).Theemployer(self−insured)covers80 48/month). Policy update (2025-2026): US FDA digital health guidance (2025) for dietary management apps (Software as a Medical Device, SaMD). EU MDR (2025) classifies CGM-integrated dietary apps as Class IIa medical devices (requires notified body assessment). China NMPA published "Technical Guidelines for Chronic Disease Digital Health Management" (2026), requiring clinical validation (n≥200) for efficacy claims (HbA1c reduction, blood pressure reduction). US Medicare Diabetes Prevention Program (MDPP) expanded coverage (2025) to include virtual dietary management (not just in-person). 4. Competitive Landscape Key players: Noom (US - psychology-based weight loss, prediabetes), Livongo Health (Teladoc, US - diabetes, hypertension, weight management), Hinge Health (US - musculoskeletal, not dietary but integrated), Dexcom (US - CGM manufacturer, API integration), Amwell (US - telehealth, chronic care management), Nutrino (US - diabetes nutrition, acquired by Noom), Zoe (US/UK - microbiome + continuous glucose monitoring, metabolic health), Lumen (Israel/US - metabolic flexibility, CO2 breath sensor), DayTwo (Israel/US - microbiome-based diabetes management), Nutritics (Ireland - dietary analysis software), Bitesnap (US - food logging, allergy), Nutrix (Switzerland - CGM + nutrition AI), Spoon Guru (UK - dietary restrictions, food discovery), Abbott (US - Freestyle Libre CGM, nutrition partnerships), Gushengtang Holdings (China - TCM-based chronic disease dietary), Dong-E-E-Jiao (China - traditional Chinese medicine nutrition), Miaoyijia Information Technology (China - chronic disease management platform), Ping An Healthcare and Technology Company (China - GoodDoctor), WeDoctor (China - WeDoctor chronic care), Shanzhen (China). Segment by Plan Type: Multi-Disease Comprehensive Plan – 60-65% market share Single Disease Management Plan – 35-40% Segment by Application: Healthcare Industry – 50-55% of demand Elderly Care Industry – 20-25% Health Science Industry – 15-20% Others – 5-10% Regional market share (2025): North America: 45-50% Europe: 25-30% Asia-Pacific: 15-20% (fastest-growing) Rest of World: 5-10% 5. Technical Hurdles and Future Directions Adherence and engagement: Digital dietary management programs have 30-50% dropout rates at 6 months. Gamification, coaching, financial incentives (US$ 10-50/month discounts), and social support improve retention to 60-70%. Personalization accuracy: Individual glycemic response to foods varies (coefficient of variation 30-50%). Microbiome-based algorithms (DayTwo, Zoe) improve prediction (R² 0.5-0.7) vs. generic (R² 0.2-0.3). CGM integration further personalizes (individual postprandial response). Reimbursement and accessibility: Employer wellness programs cover 30-40% of eligible employees (selection bias: healthier employees enroll). Medicare covers only diabetes prevention (prediabetes), not diabetes management. Expanding reimbursement requires RCT evidence (cost-effectiveness, clinical outcomes). Future priorities: AI-powered real-time dietary coaching (photo recognition, meal recommendations based on CGM trends), microbiome + metabolomics + continuous glucose monitoring (multi-omics personalization), and prescription digital therapeutics (FDA-regulated, reimbursable, for chronic disease management) are emerging. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666 (US) JP: https://www.qyresearch.co.jp